Biopharmaceutical - Clinical-stage immunotherapy development
Strategic Profile
SAB's proprietary DiversitAb platform enables rapid and efficient production of targeted human polyclonal antibodies without reliance on human plasma, a key differentiating factor. The registrational Phase 2b SAFEGUARD study for SAB-142 is on track to complete enrollment by end-2026 with topline data expected in 2H 2027, positioning the company for potential market entry in the large type 1 diabetes therapeutic space.
Cyborg Score Rationale
Analysts rate SABS as a Strong Buy consensus, reflecting confidence in SAB-142's potential. However, the company anticipates substantial operating losses driven by high R&D and clinical development costs, and execution risk remains significant as the lead candidate is still in Phase 2b trials.
Top Insights
Recently closed a $85 million underwritten public offering in March 2026 at $3.85 per share to fund SAB-142 development
Completed a $175 million oversubscribed private placement with strategic investor Sanofi and maintains $143.5 million cash position providing runway through 2028
Phase 1 data in adults with established type 1 diabetes showed early signals of C-peptide preservation at Day 120 in treated participants versus placebo with evidence of T-cell exhaustion
Wall Street analyst price target of $10.75 by March 2027 reflects optimism, though current stock trades at ~$3.48 (April 2026)
Named Competitors
Fasenra/Dupilumab — Monoclonal antibody immunotherapies for autoimmune diseases
Ocrevus — Anti-CD20 monoclonal antibody for autoimmune conditions
Thymoglobulin — Established anti-thymocyte immunoglobulin for transplant/autoimmune use
Recent Developments
(April 2026) Emergent BioSolutions enters SAB-142 development partnership with SAB Biotherapeutics
(April 2026) Positive Phase 1 SAB-142 results highlighting data at diabetes conferences
(March 2026) Closed $85 million public offering to fund clinical trials and manufacturing
(January 2026) S-3 shelf registration declared effective by SEC
Open the full interactive SAB Biotherapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.